Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Total Debt (2016 - 2025)

Historic Total Debt for Altimmune (ALT) over the last 16 years, with Q3 2025 value amounting to $14.4 million.

  • Altimmune's Total Debt changed N/A to $14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.4 million, marking a year-over-year change of. This contributed to the annual value of $4.6 million for FY2022, which is 3927.62% down from last year.
  • Per Altimmune's latest filing, its Total Debt stood at $14.4 million for Q3 2025.
  • Over the past 5 years, Altimmune's Total Debt peaked at $14.4 million during Q3 2025, and registered a low of $1.5 million during Q2 2022.
  • Over the past 4 years, Altimmune's median Total Debt value was $4.4 million (recorded in 2023), while the average stood at $5.4 million.
  • Its Total Debt has fluctuated over the past 5 years, first skyrocketed by 31259.15% in 2021, then tumbled by 3927.62% in 2022.
  • Altimmune's Total Debt (Quarter) stood at $7.5 million in 2021, then crashed by 39.28% to $4.6 million in 2022, then dropped by 6.02% to $4.3 million in 2023, then soared by 235.54% to $14.4 million in 2025.
  • Its last three reported values are $14.4 million in Q3 2025, $14.3 million for Q2 2025, and $4.3 million during Q3 2023.